Table 1.
Cumulative cancer risks in Lynch syndrome according to genotype.
| Cancer Type | MLH1 | MSH2/ EPCAM |
MSH6 | PMS2 | General Population |
|---|---|---|---|---|---|
| Colorectal cancer | 46–61% | 33–52% | 10–44% | 8.7–20% | 4.2% |
| Endometrial cancer | 34–54% | 21–57% | 16.49% | 13–26% | 2.7% |
| Ovarian cancer | 4–20% | 8–28% | ≤1–13% | 1.3–3% | 1.3% |
| Ureteral cancer | 0.2–5% | 2.2–28% | 0.7–5.5% | ≤1–3.7% | <1% |
| Gastric cancer | 5–7% | 0.2–9% | ≤1–7.9% | Not known | 0.9% |
| Pancreatic cancer | 6.2% | 0.5–1.6% | 1.4–1.6% | ≤1–1.6% | 1.6% |
| Prostate cancer | 4.4–13.8% | 3.9–23.8% | 2.5–11.6% | 4.6–11.6% | 11.6% |